Holen Sie sich die Stockscreener-App
274.81
0.99%
2.70
Handel nachbörslich:
274.70
-0.11
-0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Arcus Taps Amgen Exec Richard Markus as Chief Medical Officer - MarketWatch
Cracking Cholesterol: Biology-Driven Breakthrough Wins Rathmann Award - Amgen
Alzheimer's Drugs Market Growth: AbbVie, Amgen, and Biogen Pioneering New Therapeutic Solutions - openPR
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? - The Motley Fool
Diversify Advisory Services LLC Cuts Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Position Boosted by Diversify Wealth Management LLC - MarketBeat
Cell and Gene Therapy Market Set to Witness Significant Growth by 2025-2032: Pfizer, Inc., Sanofi S.A., Amgen, - EIN News
Amgen: Likely To Be Rangebound (Rating Downgrade) - Seeking Alpha
Corundum Group Inc. Has $1.04 Million Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Willner & Heller LLC Boosts Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer - Yahoo Finance Australia
Amgen Inc. (AMGN): A Bull Case Theory - Insider Monkey
Annex Advisory Services LLC Has $4.11 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
FDA approves Amgen’s combo therapy for colorectal cancer - Yahoo Finance
Sax Wealth Advisors LLC Makes New $252,000 Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Kelly Financial Services LLC Invests $3.78 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Here’s Why Amgen Inc. (AMGN) Is Among the Highest Yielding Dividend Stocks In the Dow - Insider Monkey
HB Wealth Management LLC Buys 1,768 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Cohen Klingenstein LLC Sells 1,750 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Verity & Verity LLC Raises Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Stock Position Trimmed by Aaron Wealth Advisors LLC - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Stock Position Lifted by Merit Financial Group LLC - MarketBeat
Why Amgen Inc. (AMGN) Is One of the Best Cheap Stocks to Buy for 2025? - Insider Monkey
Amgen picks up key colorectal cancer okay for KRAS drug - pharmaphorum
Why Is Amgen Inc. (AMGN) Among Louis Navellier’s Top Long-term Stock Picks? - Insider Monkey
Avanza Fonder AB Makes New Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Tompkins Financial Corp Buys 16,481 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Zoran Krunic, Senior Manager of Data Science at Amgen The Superposition Guy's Podcast: Workforce Development - The Quantum Insider
Boston Common Asset Management LLC Has $5.66 Million Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Householder Group Estate & Retirement Specialist LLC Has $412,000 Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Empirical Asset Management LLC Purchases 3,156 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Ritholtz Wealth Management Decreases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen's (NASDAQ:AMGN) Upcoming Dividend Will Be Larger Than Last Year's - Simply Wall St
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs - BioPharma Dive
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation - Benzinga
Amgen : Advancement in Combination Biomarker Driven Therapy for Adult Patients with Chemorefractory KRAS G12C Mutated Metastatic Colorectal Cancer (mCRC) - Marketscreener.com
FDA Approves Amgen’s LUMAKRAS + Vectibix for KRAS G12C-mutated Colorectal Cancer - Contract Pharma
FDA approves Amgen's Lumakras with Vectibix for mCRC - World Pharmaceutical Frontiers
FDA Approves Amgen's Groundbreaking LUMAKRAS Combination Therapy for Colorectal Cancer Treatment - StockTitan
Looking beyond obesity, Amgen wins colorectal cancer expansion for Lumakras - PharmaLive
FDA Greenlights Amgen's New Cancer Drug Combo, Boosting Survival for KRAS G12C Patients - GuruFocus.com
Occidental Asset Management LLC Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
1,620 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Bennett Associates Wealth Management - MarketBeat
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer - Seeking Alpha
Carnegie Investment Counsel Grows Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
JGP Wealth Management LLC Increases Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
1,041 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by Tallon Kerry Patrick - MarketBeat
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Godsey & Gibb Inc. Increases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
US FDA approves Amgen's colorectal cancer therapy - Reuters
Is Amgen Inc. (AMGN) Among the Best NASDAQ Dividend Stocks to Buy? - Insider Monkey
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Gateway Investment Advisers LLC - MarketBeat
Flywheel Private Wealth LLC Acquires New Shares in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Argent Capital Management LLC - MarketBeat
Alzheimers Drugs Market Projected To Reach USD 12.26 Bn by - GlobeNewswire
Amgen Reveals Ocrelizumab Biosimilar Ambitions - News & Insights
Wolff Wiese Magana LLC Purchases 1,644 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Avity Investment Management Inc. Decreases Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Assenagon Asset Management S.A. Cuts Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Holdings Lifted by Thurston Springer Miller Herd & Titak Inc. - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Park Avenue Securities LLC - MarketBeat
Pines Wealth Management LLC Makes New Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
SeaCrest Wealth Management LLC Lowers Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Fed. Circ. Judge Asks What's The Rush In Eylea Biosimilar Case - Law360
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - MSN
JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning - BioPharma Dive
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
1.29%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):